Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PHAS

PhaseBio Pharmaceuticals (PHAS) Stock Price, News & Analysis

PhaseBio Pharmaceuticals logo

About PhaseBio Pharmaceuticals Stock (NASDAQ:PHAS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
9.65 million shs
Average Volume
848,888 shs
Market Capitalization
$3.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PHAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PhaseBio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PHAS Stock News Headlines

MedPharm appoints Bill Humphries as new CEO
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
PhaseBio Pharmaceuticals Inc.
PhaseBio Pharmaceuticals, Inc. (PHASQ)
Alcami Announces CEO Transition
See More Headlines

PHAS Stock Analysis - Frequently Asked Questions

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) released its earnings results on Wednesday, November, 10th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by $0.07. The firm had revenue of $0.34 million for the quarter, compared to analysts' expectations of $2.67 million.

PhaseBio Pharmaceuticals (PHAS) raised $66 million in an IPO on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel served as the underwriters for the IPO and Needham was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that PhaseBio Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM), VBI Vaccines (VBIV), Oncobiologics (OTLK), Viking Therapeutics (VKTX) and Anavex Life Sciences (AVXL).

Company Calendar

Last Earnings
11/10/2021
Today
7/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PHAS
CIK
1169245
Fax
N/A
Employees
60
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$131.07 million
Net Margins
-12,572.13%
Pretax Margin
-12,572.13%

Debt

Sales & Book Value

Annual Sales
$818 thousand
Price / Cash Flow
N/A
Book Value
($1.93) per share
Price / Book
N/A

Miscellaneous

Free Float
44,922,000
Market Cap
$3.50 million
Optionable
Not Optionable
Beta
2.57
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:PHAS) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners